百诚医药(301096.SZ)：创新药BIOS-0625片获得临床试验批准通知书

智通财经2025-11-07

智通财经APP讯，百诚医药(301096.SZ)发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局(NMPA)临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其"不可根治、反复发作"的病程特征构成了持久的治疗挑战。传统药物虽能短期缓解症状，却长期受制于三大瓶颈：疗效天花板低、不良反应显著、患者耐受性差。新分子，新疗法既是改善患者生活质量的基石，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581004450?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-07 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581004450","market":"hk","top_or_hot":-1,"title":"百诚医药(301096.SZ)：创新药BIOS-0625片获得临床试验批准通知书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，百诚医药(301096.SZ)发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局(NMPA)临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其\"不可根治、反复发作\"的病程特征构成了持久的治疗挑战。传统药物虽能短期缓解症状，却长期受制于三大瓶颈：疗效天花板低、不良反应显著、患者耐受性差。新分子，新疗法既是改善患者生活质量的基石，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1366847.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百诚医药(301096.SZ)：创新药BIOS-0625片获得临床试验批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百诚医药(301096.SZ)：创新药BIOS-0625片获得临床试验批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-07 20:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1366847.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，百诚医药(301096.SZ)发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局(NMPA)临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其\"不可根治、反复发作\"的病程特征构成了持久的治疗挑战。传统药物虽能短期缓解症状，却长期受制于三大瓶颈：疗效天花板低、不良反应显著、患者耐受性差。新分子，新疗法既是改善患者生活质量的基石，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1366847.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301096","symbol_name":"百诚医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1366847.html","article_id":"2581004450","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581004450","pubTimestamp":1762519076,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，百诚医药 发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其\"不可根治、反复发作\"的病程特征构成了持久的治疗挑战。BIOS-0625片是由公司自主研发的一种全新靶点应用于治疗溃疡性结肠炎的药物，目前该靶点暂无同适应症药品上市。BIOS-0625片属于“境内外均未上市的创新药”，其注册分类为化学药品1类。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","301096":"百诚医药","BK0216":"研究试验","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Baicheng Pharmaceutical (301096. SZ): Innovative drug BIOS-0625 tablets obtained clinical trial approval notice","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"301096":1.5,"06978":1.5},"content_text":"智通财经APP讯，百诚医药(301096.SZ)发布公告，公司近日获悉，公司自主研发的创新药BIOS-0625片获得国家药品监督管理局(NMPA)临床试验批准通知书。溃疡性结肠炎作为一种慢性复发性肠道炎症性疾病，其\"不可根治、反复发作\"的病程特征构成了持久的治疗挑战。传统药物虽能短期缓解症状，却长期受制于三大瓶颈：疗效天花板低、不良反应显著、患者耐受性差。新分子，新疗法既是改善患者生活质量的基石，更是连接转化医学与病患长期获益的关键桥梁。BIOS-0625片是由公司自主研发的一种全新靶点应用于治疗溃疡性结肠炎的药物，目前该靶点暂无同适应症药品上市。BIOS-0625片属于“境内外均未上市的创新药”，其注册分类为化学药品1类。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581004450","isCrawlerRequest":true}